Asset Details
Do you wish to reserve the book?
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials
Do you wish to request the book?
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials
2025
Overview
Two single-center Phase I trials evaluated safety (primary endpoint) and preliminary efficacy (secondary endpoint) of oncolytic adenovirus Ad-TD-nsIL12 in primary (Group A, NCT05717712) and progressive (Group B, NCT05717699) pediatric patients with IDH wild-type (WT) diffuse intrinsic pontine glioma (DIPG). Studies employed single-arm and 3 + 3 dose-escalation design. 9 patients were enrolled in Group A and 6 in Group B. Group A completed the dose escalation, and no severe adverse events were observed. Enrollment in Group B was halted after Group A completed escalation. All patients experienced drug-related adverse events. In Group A, three partial responses and five stable diseases were documented, with a median overall survival (mOS) of 10.3 months after the first virus and 11.3 months after onset. In Group B, three patients had stable diseases, and three had progressive disease, with an mOS of 6.4 months after the first virus and 12.7 months after onset. Both groups demonstrated improved mOS from onset compared to the DIPG patients in our center’s retrospective study (mOS, 8.3 months). Both groups showed increased lymphocytes post-treatment, but only Group A decreased after radiotherapy. These trials confirmed the safety of Ad-TD-nsIL12 and provided preliminary efficacy evidence, offering insights for future clinical applications in DIPG.
Bioelectronic sensors can use bacteria to detect toxins as electrical signals but are limited to single analytes. Here, the authors combine synthetic biology and electrochemistry to create a multi-channel bioelectronic sensor that detects multiple toxins and encodes digital output.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 82/51
/ 96/31
/ Biopsy
/ Brain Stem Neoplasms - genetics
/ Brain Stem Neoplasms - mortality
/ Brain Stem Neoplasms - pathology
/ Brain Stem Neoplasms - therapy
/ Child
/ Diffuse Intrinsic Pontine Glioma - genetics
/ Diffuse Intrinsic Pontine Glioma - mortality
/ Diffuse Intrinsic Pontine Glioma - pathology
/ Diffuse Intrinsic Pontine Glioma - therapy
/ Female
/ Glioma
/ Humanities and Social Sciences
/ Humans
/ Isocitrate Dehydrogenase - genetics
/ Male
/ Mutation
/ Oncolytic Virotherapy - adverse effects
/ Oncolytic Virotherapy - methods
/ Oncolytic Viruses - genetics
/ Patients
/ Science
/ Toxins
/ Tumors
